Celmatix, Inc., the leading women’s health biotechnology company focused on ovarian biology, has announced a breakthrough in its novel oral fertility drug program. The program aims to eliminate follicle stimulating hormone (FSH) injections from in vitro fertilization (IVF) and egg freezing protocols, as well as reduce the need for IVF by improving outcomes with ovulation induction and treating male infertility directly.
The new drug program developed by Celmatix focuses on developing the world's first oral FSH receptor (FSHR) agonist drug. This innovative product has the potential to revolutionize fertility treatments and was announced at the annual meeting of the European Society of Human Reproduction and Embryology (ESHRE).
Dr. Piraye Yurttas Beim, Founder and CEO of Celmatix, stated that the goal is to eliminate injections during ovarian stimulation for procedures like egg freezing and IVF. Additionally, they aim to provide a more effective strategy for restoring ovulatory function in women with conditions like polycystic ovary syndrome (PCOS) and address male infertility by advancing their program to increase sperm count